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Abstract
Coenzyme Q10 (CoQ10) and L-carnitine are very important biologically active 
compounds involved in energy metabolism. L-carnitine and coenzyme Q10 distur-
bances in mitochondrial diseases require the correction. Patients and methods: The 
levels of coenzyme Q10 and L-carnitine (total carnitine, free carnitine, and acyl-
carnitines) were determined in children with mitochondrial diseases (25 children 
and 16 children, respectively). High-performance liquid chromatography with UV 
detection (chromatograph Shimadzu Nexera LC-30) and chromatography-mass 
spectrometry (Agilent 6410 QQQ , USA) were used. As an additional parameter of 
possible coenzyme Q10 and carnitine insufficiency, the coenzyme Q10/cholesterol 
ratio and acylcarnitines/free carnitine ratio were calculated. Results: A significantly 
low ratio of coenzyme Q10/cholesterol in children with mitochondrial diseases 
was revealed—0.10 ± 0.01 vs. 0.19 ± 0.01 in the control group (p < 0.001). A lower 
absolute level of coenzyme Q10 and tendency toward a more pronounced decrease 
in the Q10/cholesterol ratio in older patients (6–16 years) were shown. The free 
carnitine blood level was within the normal range and averaged at 29.8 ± 2.6 μmol/l; 
however, the level was lower than that in the control group (44 ± 5.2 μmol/l, 
p < 0.05). A pronounced significant increase in the acylcarnitines/free carnitine 
ratio was determined—1.5 ± 0.05 (the normal range < 0.6).
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1. Introduction
Mitochondrial diseases are a large heterogeneous group of pathological condi-
tions caused by genetically determined defects in the mitochondria’s structure and 
function in the release of the energy of organic substances and its accumulation 
in the form of macroergic phosphate compounds by the generation of adenosine 
triphosphate [1]. These disorders can be due to mutations in mitochondrial DNA or 
due to mutations in nuclear DNA. Some mitochondrial diseases are rare. However, 
in general, mitochondrial encephalopathy is the most common neurometabolic 
disorder [2]. Defects in the respiratory chain and oxidative phosphorylation are the 
basis of the pathogenesis of these severe diseases.
Mitochondrial diseases have a wide range of clinical presentations with a gener-
ally poor prognosis: failure to thrive, encephalopathy, respiratory insufficiency, 
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hypotonia, ataxia, seizures, cardiac involvement, hepatopathy and nephropathy, 
sensorineural hearing loss, retinopathy, lesions of the basal ganglia, and others. The 
common laboratory signs are lactic acidosis, hypo- or hyperglycemia (diabetes), 
elevated creatine kinase and aminotransferases, and urine organic acid/amino acid 
abnormalities [3].
Current therapies are frequently inefficient and mostly palliative. The treat-
ment strategy for mitochondrial diseases is to improve the efficiency of biological 
processes in the respiratory chain and oxidative phosphorylation. Patients are 
prescribed complex treatment, including drugs that affect different stages of energy 
metabolism. This treatment approach shows a higher positive effect than mono-
therapy [4]. Coenzyme Q10 and L-carnitine are very important biologically active 
substances involved in energy metabolism. So, coenzyme Q10 and L-carnitine are 
often recommended for the treatment of mitochondrial diseases [5]. However, some 
authors acknowledge the lack of rationale behind these recommendations since the 
data from randomized clinical trials are still lacking.
2. Functions of CoQ10 and its biological role
Coenzyme Q10 is the most common ubiquinone in the human body. Its structure 
contains a quinoid ring and 10 isoprenyl groups. Coenzyme Q10 is structurally 
similar to vitamins E and K. Coenzyme Q10 exists in oxidized (ubiquinone) and 
reduced (ubiquinol) forms and is known to be a constituent of the biological mem-
branes [6]. Coenzyme Q10 is one of the main components of the electron transport 
chain of mitochondria. In the form of ubiquinone, it acts as an electron transporter 
from Complex I and Complex II to Complex III. In this process, the formation of the 
reduced form—ubiquinol—occurs. Ubiquinol is a powerful antioxidant, which has 
a protective effect on biological membranes, regulates their permeability, inhibits 
peroxidation of plasma lipoproteins, and provides a recovery of tocopherol activity 
[6, 7]. According to the recent data, coenzyme Q10 is reported to be involved in the 
regulation of some gene expression and inflammatory mediators, in particular, by 
influencing the transcription factor NFkappaB1; its participation in DNA replica-
tion and repair was shown [8, 9].
In mammals, the largest amount of coenzyme Q10 is found in the heart and 
skeletal muscles. In the peripheral blood, coenzyme Q10 is bound to lipoproteins, 
and its level is positively correlated with total cholesterol [10, 11].
Most of the body’s daily coenzyme Q10 requirement is derived from endogenous 
synthesis; small amounts of coenzyme Q10 are obtained from foods such as meat, 
fish, and nuts. Biosynthesis is a multi-step process, taking place on the inner mito-
chondrial membrane. Vitamins B2, B3, B6, B12, and C and folic and pantothenic 
acids are known to participate in the coenzyme Q10 biosynthetic pathway under the 
control of a dozen genes. The intensity of biosynthesis declines substantially with 
age [12, 13].
3. Coenzyme Q10 deficiency in disorders: the possibility of diagnosis
Primary coenzyme Q10 deficiency is due to a defect in its biosynthesis. These 
diseases form a separate group of mitochondrial diseases and are associated with 
mutations in multiple genes including PDSS1, PDSS2, CoQ2, CoQ6, CoQ9, and 
ADCK3. These diseases are characterized by a decrease in the level of coenzyme 
Q10 in tissues and in fibroblasts whereas the blood levels can be normal [11, 14, 15]. 
Secondary coenzyme deficiency with low plasma and tissue coenzyme Q10 levels 
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can occur in patients taking anticancer agents and statins. The hypocholesterolemic 
effect of statins is due to the inhibition of 3-hydroxy-3-methylglutaryl-COA reduc-
tase and a disruption of the synthesis of mevalonic acid, which is one of the precur-
sors of not only cholesterol but also ubiquinone. Approximately a half of patients 
receiving statins show a decrease in coenzyme Q10 in the muscle tissue; myalgia 
and myoglobinuria may also be observed [16, 17].
Secondary coenzyme Q10 deficiency and low levels of coenzyme Q10 in plasma 
and tissues are found in certain diseases of older age (Parkinson’s and Alzheimer’s 
disease, atherosclerosis, diabetes mellitus, etc.) [13, 18, 19], in some hereditary dis-
eases, including inborn errors of metabolism— mevalonic aciduria, phenylketon-
uria, glutaric acidemia II, ataxia-oculomotor apraxia 1, and cardiofaciocutaneous 
syndrome [11, 20]. Coenzyme Q10 deficiency in mevalonic aciduria and in phenyl-
ketonuria can be explained by insufficient cholesterol production: the decrease in 
the activity of mevalonate kinase and the inhibition of 3-hydroxy-3-methylglutaryl-
COA reductase with high levels of phenylalanine, respectively. In phenylketonuria, 
ubiquinone deficiency may well be exogenous due to dietary restrictions such as 
avoidance of animal products [10].
A decrease in coenzyme Q10 was reported in the peripheral blood and 
muscles in some (20–40%) patients with mitochondrial pathology associated 
with mutations and depletion of mitochondrial DNA [21, 22]. Of interest, in 
children with myopathy due to other causes, there were no changes in the content 
of coenzyme Q10 in the muscles, except for the patients with Duchenne muscular 
dystrophy [23].
The coenzyme Q10 deficiency can be detected in biological fluids (plasma or 
serum), fibroblasts, and muscle tissue. However, the blood level of coenzyme Q10 is 
not considered as a reliable indicator of its state in the body. There is no clear corre-
lation between the levels of ubiquinone in plasma and muscle tissue. This parameter 
is influenced by the lipid intake from foods and the blood levels of cholesterol and 
low-density lipoproteins [7, 10, 11]. Therefore, the ratio of coenzyme Q10 to cho-
lesterol and low-density lipoproteins is proposed for clinical use. Apparently, the 
measurement of coenzyme Q10 in the peripheral blood mononuclear cells appears 
to be a promising detection method.
4.  Low blood level of coenzyme Q10 as a diagnostic marker of 
mitochondrial encephalomyopathy and the rationale for therapy
In the Research and Clinical Institute of Pediatrics, an examination of 16 
children (group 1) aged 1–16 years (average age 8.3 ± 1.5 years) with mitochondrial 
diseases was performed.
In nine children, the disease was caused by deletions or point mutations of 
mitochondrial DNA: Kearns-Sayre syndrome (common deletion of mitochondrial 
DNA) in three; mitochondrial encephalomyopathy with pyramidal-extrapyramidal 
syndrome (MTND1 mutation) in two; mitochondrial encephalomyopathy with 
cardiomyopathy (MTTK mutations) in two; mitochondrial myopathy, encephalop-
athy, lactic acidosis, and stroke-like episodes (MTTL1 mutation) in 1; and maternal 
inherited Leigh syndrome (MTND3 mutation) in 1.
Seven children were diagnosed with mitochondrial diseases of nuclear origin: 
leukoencephalopathy with brain stem and spinal cord involvement and lactate 
elevation (DARS2 mutations) in four and Leigh syndrome (SURF1 mutations) 
in three.
The comparison group (group 2) consisted of 13 children with neurodegenera-
tive diseases aged 1–15 years (mean age 6.4 ± 1.3 y): 6 children with neuronal ceroid 
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lipofuscinosis 2 (TPP1 mutations), 2 with sialidosis type 2 (NEU1 mutations), and 5 
with progressive ataxia not genetically confirmed. The control group (group 3) con-
sisted of 29 healthy children aged 1–16 years (mean age 7.4 ± 0.8 y) who underwent 
a routine examination at the health center (an informed consent of the parents was 
obtained) [24]. The ratio of boys:girls is 16:13. There was no statistically significant 
difference in the average age between the three groups.
A detailed work-up of the patients of the first two groups included clinical 
(pedigree, neurological, cardiological, and other examinations) examination and 
biochemical tests. In all children, the plasma level of coenzyme Q10 was determined 
by high-performance liquid chromatography with UV detection (chromatograph 
Shimadzu Nexera LC-30). The blood cholesterol level was determined photo-
metrically (analyzer Konelab Prime 60i), followed by the calculation of the coen-
zyme Q10/cholesterol ratio. The DNA diagnosis of diseases was carried out in the 
laboratory of inborn errors of metabolism of Research Centre for Medical Genetics 
(Moscow, Russia).
Statistical data processing was carried out by methods of variation statistics and 
correlation analysis (Statistica, Excel 7.0). Student’s t-test was used to assess the 
statistical significance of the data, and the differences were considered statistically 
significant at p < 0.05.
The blood levels of coenzyme Q10 in children with mitochondrial diseases 
(group 1) were 0.56 ± 0.05 μmol/l (Table 1) and did not differ from that in the 
control group but was significantly lower (p < 0.01) than that in children with 
neurodegenerative diseases (group 2). The blood level of coenzyme Q10 in children 
with neurodegenerative diseases was 1.53 ± 0.23 μmol/l and significantly exceeded 
that in healthy children (p < 0.01).
The blood cholesterol level in patients of the first and second groups was 
significantly higher than that in healthy children (p < 0.01). The ratio of coenzyme 
Q10/cholesterol was severely impaired compared with that in healthy children (see 
Table 1). This parameter was significantly decreased in patients with mitochondrial 
diseases (0.10 ± 0.01 vs. 0.19 ± 0.01, p < 0.001) but increased in those with neuro-
degenerative diseases (0.31 ± 0.04, p < 0.002).
For the subgroup analysis, children aged 1–5 and 6–16 years were analyzed 
separately within each group (Table 2). In healthy children (group 3), there were 
no age-related differences.
In the group of older patients with mitochondrial diseases, the blood level 
of coenzyme Q10 was significantly lower than that in the younger subgroup 
(p < 0.05) and was significantly different from its level in children in the second 
Groups of 
children
Levels in the blood
Coenzyme Q10, μmol/l Cholesterol, 
μmol/l
Coenzyme Q10/cholesterol
Group 1, n = 16 0.56 ± 0.05 5.7 ± 0.32 0.10 ± 0.01
Group 2, n = 13 1.53 ± 0.23 4.8 ± 0.31 0.31 ± 0.04








1-2p, 1-3p, and 2-3p - significance of differences between groups (1-2, 1-3, and 1-3)
Table 1. 
Coenzyme Q10 and cholesterol levels (M ± m) in the blood of the examined children.
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(p < 0.001) and third (p < 0.05) groups of the same age. In addition, older 
patients (6–16 years) tend to have lower cholesterol levels and lower coenzyme 
Q10/cholesterol ratios than younger patients (1–5 years). In the group of children 
with mitochondrial encephalomyopathies, there was a negative correlation 
between the blood level of coenzyme Q10 and cholesterol and the patient’s age 
(r = −0.54 and r = −0.48, respectively; p < 0.05). There were no differences in 
the studied parameters between children with mitochondrial diseases caused 
by mutations of mitochondrial (n = 9) and nuclear (n = 6) DNA. By age, these 
subgroups were not different.
In the group of children with neurodegenerative diseases, the opposite tendency 
was observed toward higher rates of coenzyme Q10, cholesterol, and their ratios in 
patients of the older subgroup (see Table 2); unreliability of differences seems to 
be associated with a small number of patients. A positive correlation between the 
blood levels of coenzyme Q10 and cholesterol (r = 0.66; p < 0.05) was established. 
These parameters correlated positively with the age of the patients (r = 0.37 and 
r = 0.41, respectively; p < 0.05).
To sum up, our study demonstrated that the average level of coenzyme Q10 in 
patients with mitochondrial diseases did not differ from that in healthy children. 
However, these patients had a higher cholesterol level and, as a result, a reduced 
ratio of coenzyme Q10/cholesterol. In patients of the older subgroup (6–16 years), 
the changes were more pronounced: significantly lower levels of coenzyme Q10 
and a tendency toward a lower Q10/cholesterol ratio than the younger subgroup 
(1–5 years).
In children with neurodegenerative diseases (not caused by primary mitochon-
drial dysfunction), the level of cholesterol (as well as in the first group) was higher 
than that in healthy children. Other test results differed considerably from those in 
patients with mitochondrial pathology. High blood level of coenzyme Q10 and an 




































Age 1–5 years, n = 15 0.64 ± 0.04 3.5 ± 0.16 0.19 ± 0.02
Age 6–16 years, n = 14 0.69 ± 0.07 3.6 ± 0.18 0.20 ± 0.02
*Significant difference from the older age subgroup; р < 0.05. 1-2p, 1-3p, and 2-3p - significance of differences between 
groups (1-2, 1-3, and 1-3)
Table 2. 
Coenzyme Q10 and cholesterol levels (M ± m) in the blood in children of different age subgroups.
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increase in the coenzyme Q10/cholesterol ratio were revealed, and these changes 
increased with age.
Due to a small sample size, the obtained data were considered as preliminary. 
Nevertheless, our results revealed a coenzyme Q10 deficiency in children with mito-
chondrial diseases and emphasized the difference in the pathogenesis of primary 
mitochondrial diseases and neurodegenerative diseases of non-mitochondrial ori-
gin. In both patient groups, the age-related aggravation of these changes was noted 
to correspond to a progressive disease course. The similarity of clinical manifesta-
tions underlies the difficulties in the differential diagnosis between mitochondrial 
encephalomyopathies and neurodegenerative diseases. The detection of the plasma 
coenzyme Q10 level can be helpful in the differential diagnosis between these 
conditions.
In addition, a low coenzyme Q10/cholesterol ratio and a tendency toward a 
decrease in the coenzyme Q10 levels with age suggest its insufficiency in patients 
with progressive mitochondrial encephalomyopathy. This provides a rationale for 
the use of coenzyme Q10 in the treatment of patients with mitochondrial diseases.
5. Functions of carnitine and its biological role
Carnitine (β-hydroxy-γ-trimethylaminobutyric acid) is a low molecular weight 
compound, which is crucial for energy metabolism in the human body. As an 
L-stereoisomer, carnitine is present in various tissues. Endogenous carnitine forma-
tion occurs in the liver, kidney, and brain cells through the transformation of the 
amino acids lysine and methionine, with a glycine involvement. Vitamins C, B6, and 
B3 and iron ions are the cofactors for carnitine biosynthesis. The biosynthesis steps 
are under the control of mitochondrial enzymes (trimethyl-lysine deoxygenase, 
3-OH-trimethyl-lysine aldolase, 4-trimethylaminobutanal dehydrogenase, butyr-
obetaine dioxygenase) [25]. However, biosynthesis provides only a part of carnitine 
daily requirements, and the main source of its intake is animal foods including red 
meat, fish, and dairy products. Carnitine absorption in the gastrointestinal tract, 
tubular reabsorption, and delivery to the tissue are provided by transport proteins, 
with OCTN2 being the main carnitine transporter. Carnitine is transported to the 
skeletal muscles and myocardium—these tissues contain the main reserves of carni-
tine, due to their high activity of lipid metabolism [26]. The importance of carnitine 
for the body is evidenced by its almost complete reabsorption in the renal tubules.
Studies have established the value of carnitine for the processes of biological oxi-
dation and maintenance of mitochondrial functions in the human body. Carnitine 
is crucial in conditions of a high energy consumption. These conditions such as 
intercurrent diseases, increased physical activity, starvation, etc. are characterized 
by increased catabolism. After depletion of carbohydrate reserves, lipids become 
the main sources of the ATP synthesis in the body.
One of the main vital functions of carnitine is bioenergetics. Carnitine is 
involved in lipid catabolism, providing its initial stages—an activation and a 
transfer of long-chain fatty acids from the cytoplasm through the outer and inner 
mitochondrial membranes to the mitochondrial matrix, thereby making them 
available for subsequent β-oxidation to form acetyl-CoA. In addition, fatty acid 
oxidation is the main pathway of ketogenesis, and ketone bodies are an additional 
energy substrate for peripheral tissues and the brain [26, 27].
The effect of carnitine on fat metabolism occurs through its participation in 
the cytoplasmic synthesis of fatty acids. Carnitine provides the reverse transfer of 
acetyl groups of mitochondrial acetyl-CoA through the mitochondrial membrane 
into the cytoplasm.
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An important function of carnitine is due to its ability to bind acyl radicals. 
Thus, carnitine regulates tissue energy metabolism, affecting the ratio of acyl-
CoA/free CoA in the mitochondria. Likewise, the detoxifying role of carnitine is 
achieved through binding of organic acid derivatives (intermediates in oxidative 
processes) and its excretion from the cell. These organic acid derivatives, accumu-
lating in the mitochondria and cytoplasm, have an adverse effect, by inhibiting the 
enzyme activity.
Carnitine appears to play an important role in the permeability of mitochondrial 
membranes. The protective impact of carnitine relies on the prevention of a nega-
tive membranotropic action of toxic agents, inhibitors of complexes of a mitochon-
drial respiratory chain (3-nitropropionic acid, methylphenylpyridine, and others), 
and inducers of apoptosis (long-chain fatty acid radicals). Carnitine supplementa-
tion in experimental animals prevents these disorders or significantly reduces their 
severity and prevents a degenerative damage to the nervous tissue [28–31].
In addition, a favorable impact of carnitine on the cytokine production and on 
vascular endothelium was revealed. Carnitine is capable of restoring endothelial 
function and preventing of vascular remodeling caused by a decrease in nitric 
oxide production [25, 32, 33]. Apparently, the carnitine functions require further 
research.
6. Carnitine deficiency in diseases
There are primary and secondary carnitine deficiencies. The primary deficiency 
is due to an autosomal recessive defect of the gene SLC22A5, which is expressed in 
the skeletal muscles, heart, and kidneys. The gene SLC22A5 encodes a transport 
protein OCTN2, the sodium-dependent organic cation transporter. The genetic 
defect disrupts the transport of carnitine into the tissues and reabsorption in the 
renal tubules. The clinical manifestations of the disease include cardiomyopathy, 
skeletal myopathy, fatty liver, and kidney dystrophy [34].
The causes of secondary carnitine deficiency are diverse and associated with an 
interruption of endogenous synthesis and disturbance of absorption from food and 
of retention in the body, as well as with an increased excretion through the kidneys 
or gastrointestinal tract [35]. The activity of endogenous carnitine biosynthesis 
depends on the function of the liver and kidneys. Biosynthesis decreases with 
malnutrition due to a protein deficiency. Carnitine removal is enhanced in stress, 
intercurrent diseases, and impaired renal tubular function. Low blood carnitine 
level is determined in children with epilepsy treated with valproate, in patients with 
heart failure, and in patients on hemodialysis [36–38].
Secondary insufficiency occurs in inborn errors of metabolism. In particular, 
secondary carnitine insufficiency is characteristic for a large group of hereditary 
diseases of organic and fatty acid metabolism. In these diseases, low levels of carni-
tine in the peripheral blood and tissues result from the accumulation of acylcarni-
tines and their enhanced renal excretion [34, 39].
7.  The carnitine insufficiency in children with mitochondrial 
encephalomyopathies
Some patients with mitochondrial diseases (about one-fourth patients) were 
reported to have a decrease in carnitine levels in the peripheral blood [40, 41]. Our 
study was designed to diagnose and treat carnitine insufficiency in patients with 
mitochondrial diseases; to achieve this, we analyzed the clinical parameters and 
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laboratory findings of 40 children aged 2–15 years: 25 with mitochondrial encepha-
lomyopathies (group 1) and 15 with congenital myopathies (group 2). Group 1 
consisted of 10 children with Kearns-Sayre syndrome (common deletion of mito-
chondrial DNA); 2 with mitochondrial myopathy, encephalopathy, lactic acidosis, 
and stroke-like episodes (MTTL1 mutation); 1 with myoclonic epilepsy associated 
with ragged-red fibers (MTTK mutation); 5 with leukoencephalopathy with brain 
stem and spinal cord involvement and lactate elevation (DARS2 mutations); 1 with 
Barth syndrome (TAZ mutation); 3 with Leigh syndrome (SURF1 mutations); and 3 
with POLG-related diseases (mitochondrial recessive ataxia syndrome in 2 and auto-
somal recessive progressive external ophthalmoplegia in 1). Group 2 consisted of 10 
children with central core disease and 5 with minicore myopathy. The control group 
included 10 children without mitochondrial diseases or congenital myopathies, who 
attended the clinic.
The clinical examination included pedigree, neurological, cardiological, and 
other examinations. In all children, acid–base balance of the blood and the level of 
lactic and pyruvic acids were determined. The level of L-carnitine—total carnitine, 
free carnitine (C0), and acylcarnitines (AC)—in dry blood spots was measured by 
chromatography-mass spectrometry (Agilent 6410 QQQ , USA). As an additional 
parameter of a possible carnitine insufficiency, the ratio AC/C0 was calculated. 
The DNA diagnosis of mitochondrial diseases was carried out in the laboratory of 
inborn errors of metabolism of the Research Centre for Medical Genetics (Moscow, 
Russia). Structural myopathy was diagnosed using a morphological study of muscle 
tissue (light and electronic microscopy, histochemical methods).
Statistical data processing was carried out by methods of variation statistics and 
correlation analysis (Statistica, Excel 7.0). Student’s t-test was used to assess the 
statistical significance of the data, and the differences were considered statistically 
significant at p < 0.05.
In children with mitochondrial diseases, the clinical presentations of the ner-
vous and muscular system involvement prevailed: fast fatigability, low exercise 
tolerance, muscle weakness and hypotension, and a development delay. Severe 
psychomotor retardation was noted in three children with Leigh syndrome. Most 
patients had ataxia, ophthalmoplegia, headaches and vomiting, and heart damage 
(atrioventricular blockade, cardiomyopathy). Some patients had a short stature, 
seizures, retinitis pigmentosa, a hearing loss, and an impaired liver function with a 
moderate increase in blood aspartate and alanine aminotransferase.
Compensated metabolic acidosis was detected in 12 of 25 children. Elevated 
blood lactate levels were noted within the range 2.9–6.7 mmol/l in 20 children 
(the normal range 1.0–1.7 mmol/l). In 11 patients, the pyruvate level was elevated 
(0.19–0.39 mmol/l, norm 0.09–0.12 μmol/l).
In children with mitochondrial diseases, the total carnitine blood levels 
(Figure 1) ranged from 39.1 to 95.3 μmol/l, averaging (M ± m) 75.8 ± 6.2 μmol/l 
(in the control group—from 41.1 to 119.9 μmol/l; 73.7 ± 9.7 μmol/l). There was a 
negative correlation between the total carnitine and lactate in the peripheral blood 
of patients with mitochondrial diseases (r = −0.65; p < 0.05).
The free carnitine blood level was within the normal range (19–60 μmol/l) and 
averaged at 29.8 ± 2.6 μmol/l; however, the level was lower than that in the control 
group (44 ± 5.2 μmol/l, p < 0.05). In six patients, the free carnitine blood level was 
at the lower limit of the normal range, not exceeding 25 μmol/l.
The average acylcarnitine level was 44.5 ± 3.7 μmol/l (see Figure 1); 87% of 
acylcarnitines were represented by acetylcarnitine (C2). Acetylcarnitine level was 
38.7 ± 3.9 μmol/l (higher than that in control group; p < 0.05); its level in four 
children went beyond the limit of the normal range (56.3, 60.2, 64.5, 65.7 μmol/l at a 
rate of up to 50 μmol/l).
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About a half (13) of the patients had elevated levels of other acylcarnitines: 
methylmalonyl-(C4DC), tiglyl-(C5: 1), glutaryl-(C5DC), hydroxybutyryl-(C4OH), 
hydroxyisovaleryl-(C5OH), and hexanoyl-(C6); there was an increase in the blood 
levels of alanine, glycine, and leucine. These metabolic changes are likely to be 
associated with the activation of ketogenesis, an impaired metabolism of lactate and 
pyruvate in mitochondrial diseases.
On average, the proportion of free carnitine was merely 39% of the total blood 
carnitine (the normal range is 70–80%). The proportion of acylcarnitines was 61%, 
significantly exceeding that of healthy subjects (20–30%).
The ratio of acylcarnitines and free carnitine AC/C0 was markedly increased 
to 1.3–1.8, reaching an average of 1.5 ± 0.05 (the normal range < 0.6). The increase 
in this ratio suggests the relative insufficiency of free carnitine and confirms the 
accumulation of esterified forms in the total carnitine pool.
In the patients with congenital myopathies, the clinical presentations predomi-
nantly included myopathic manifestations, impaired motor development, and 
increased fatigue. Moderately elevated blood lactate levels were found in eight 
children (1.9–2.8 mmol/l, the normal range 1.0–1.7 mmol/l). In 10 patients, the 
pyruvate level was increased (0.17–0.5 mmol/l, norm 0.09–0.12 mmol/l).
The total carnitine blood levels in children ranged from 46.7 to 106.1 μmol/l, 
averaging at (M ± m) 71.4 ± 3.5 μmol/l. There was no difference in total carnitine 
level between the patients with congenital myopathies and the control group.
The mean free carnitine level of 35.0 ± 1.9 μmol/l was within the normal 
range, but it was lower than that in the control group (p < 0.05). In two children 
with structural myopathy, free carnitine level was at the lower limit of the 
normal range.
The mean level of acylcarnitines was normal (36.9 ± 2.4 μmol/l). Likewise, the 
level of acetylcarnitine is not elevated. Of note, levels of other acylcarnitines were 
moderately elevated in three patients.
The proportion of free carnitine in the total carnitine was reduced—49% (the 
normal range 70–80%). The proportion of the esterified forms accounted for 51% 
of the total carnitine, which significantly exceeded the corresponding values of 
healthy individuals (20–30%). The ratio of acylcarnitines and free carnitine AC/C0 
was increased to 0.9–1.7, averaging at 1.1 ± 0.08 (norm <0.6), which was consistent 
with carnitine insufficiency. In the control group of conditionally healthy children, 
Figure 1. 
Comparison of carnitine levels (μmol/l) in dry blood spots in children of three groups. * significant difference 
(p < 0.05) with groups 2 and 3. ** significant difference (p < 0.05) with group 3.
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the ratio of AC/C0 was 0.66 ± 0.03 and was significantly different from that in 
groups 1 and 2 (p < 0.01).
The comparison of the carnitine parameters in patients with mitochondrial 
encephalomyopathies and congenital myopathies showed that in mitochondrial 
diseases, carnitine deficiency was more pronounced. Although the levels of acyl-
carnitines, free and total carnitine, were not significantly different, in the group of 
children with mitochondrial diseases, there was a tendency for an accumulation of 
bound carnitine and a lower level of free carnitine. Additionally, an acetylcarnitine 
level was significantly higher, and the impairment of total carnitine composition 
was more pronounced in children with mitochondrial diseases than in those with 
congenital myopathies. This was confirmed by a higher ratio of AC/C0 (1.5 ± 0.05 
vs. 1.1 ± 0.08; p < 0.01).
The detection of carnitine deficiency underscores the need for L-carnitine 
therapy. L-carnitine per os in a dose of 30–50 mg/kg/day (depending on age) was 
included in the complex of energy treatment (coenzyme Q10, succinates, vitamin 
B) of patients with mitochondrial diseases. Within 1 year, three courses of therapy 
(for 2 months) were prescribed with a period off treatment for 1–2 months.
After 10–12 months of a follow-up of 18 children, a distinct improvement in one 
third of the patients was demonstrated: a reduction of fatigue, an improvement of 
exercise tolerance, and a reduction in the frequency of headache and nausea attacks. 
In one half cases, a stabilization with minimal positive dynamics was observed. These 
15 children showed a decrease in the blood lactate level to 1.4–2.3 mmol/l. At the 
same time, in three children with Leigh syndrome, despite the treatment, a moderate 
progression of the disease with a persistent lacticidemia was observed.
The total carnitine remained at the same level (70.5 ± 5.1 μmol/l); a tendency 
(p > 0.05) toward an increase in the free carnitine level (36.2 ± 2.9 μmol/l) and a 
decrease in the acylcarnitine level (34.3 ± 4.1 μmol/l), including acetylcarnitine, was 
noted. A significant improvement in the AC/C0 ratio was revealed—a decrease to 
0.9 (p < 0.001); the proportion of free carnitine in total carnitine increased signifi-
cantly to 52% (p < 0.01). In general, the data indicate favorable changes: a reduction 
in carnitine deficiency, an improvement of its function, and a reduction in ketogen-
esis and in the severity of lactate metabolism disorders.
8. Conclusion
Coenzyme Q10 and carnitine are important components of energy metabolism 
that are involved in many biological processes in the human body. Our data suggest 
that there is an insufficiency of these compounds in patients with mitochondrial 
diseases. Our studies have not revealed the severe deficiency of these substances, 
while the evidence for a relative insufficiency were found. According to our labora-
tory data, coenzyme Q10 deficiency is manifested by a significantly low ratio of 
coenzyme Q10/cholesterol. Lower absolute level of coenzyme Q10 and tendency 
toward a more pronounced decrease in the Q10/cholesterol ratio in older patients 
(6–16 years), in our opinion, are consistent with the progressive course of mito-
chondrial pathology.
Carnitine deficiency is manifested by a tendency toward a decrease in the free 
carnitine blood level, a pronounced decrease in its proportion in total carnitine, and 
a significant increase in the ratio of bound and free carnitines.
The coenzyme Q10 and free carnitine insufficiency certainly adversely affects 
the course of the disease. The causes for these disorders remain unclear. Perhaps, 
defective mitochondria are not able to provide adequate biosynthesis of coenzyme 
Q10. Depletion of free carnitine is likely to occur as a result of the activation of 
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conjugation of acyl radicals, which accumulate in the disorders of respiratory chain 
and oxidative phosphorylation.
Given a crucial role of carnitine and coenzyme in mitochondrial energy pro-
cesses, the insufficiency of these compounds should be treated. Clinical heteroge-
neity of mitochondrial diseases justifies further research in homogeneous patient 
groups in order to develop evidence-based recommendations and ensure higher 
treatment efficacy. Furthermore, a moderate carnitine deficiency in congenital 
structural myopathies provides indications for carnitine supplementation.
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